Skip to main content
. 2017 Jun 6;8(4):793–810. doi: 10.1007/s13300-017-0270-7

Fig. 2.

Fig. 2

HbA1c change from baseline (%) through week 24 by background AHA; a sulfonylurea; b glinide; c biguanide; d thiazolidinedione; e α-glucosidase inhibitor; filled circle omarigliptin, open circle placebo; based on the longitudinal data analysis model described in the “Statistical Analyses” section